Compare Stocks

EnviroMetal Technologies Inc. develops and markets technologies for the extraction of precious and other valuable metals from the mine products and electronic waste in the primary and secondary metal sectors. The company's technologies are used in the electronic waste processing industry to recover gold and other valuable metals from PCBA; and the mining industry for the recovery of gold from of ores and concentrates. It also operates E-waste and mineral processing facility. The company was formerly known as EnviroLeach Technologies Inc. and changed its name to EnviroMetal Technologies Inc. in August 2021. EnviroMetal Technologies Inc. was incorporated in 2016 and is headquartered in Burnaby, Canada.

The First Trust Preferred Securities and Income ETF (FPE) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is an actively managed fund that attempts to generate income by investing globally in preferred equities and income producing debt across the market cap spectrum. FPE was launched on Feb 12, 2013 and is managed by First Trust.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Linde Aktiengesellschaft operates as a gases and engineering company worldwide. It operates in two divisions, Gases and Engineering. The Gases division produces and distributes atmospheric gases oxygen, nitrogen, and argon; and hydrogen, acetylene, carbon monoxide, carbon dioxide, shielding gases, noble gases, and high-purity specialty gases for use in industry, commerce, science, and research sectors, as well as develops and distributes procedures and systems for gas applications. This division also offers pharmaceutical and medical gases and services to the healthcare industry; and support services, technical equipment, and safety products, as well as develops hydrogen technology. The Engineering division provides planning, project development, and construction services with a focus on market segments, such as olefin, natural gas, air separation, and hydrogen and synthesis gas plants. This division's plants are used in various fields, including the petrochemical and chemical industries; in refineries and fertilizer plants; to recover air gases; to produce hydrogen and synthesis gases; to treat natural gas; and to produce noble gases. Linde Aktiengesellschaft is headquartered in Munich, Germany. As of October 31, 2018, Linde Aktiengesellschaft operates as a subsidiary of Linde plc.

SGL Carbon SE, together with its subsidiaries, engages in the manufacture and sale of special graphite, carbon fibers, and composite products in Germany, rest of Europe, the United States, China, rest of Asia, and internationally. The company operates in four segments: Graphite Solutions, Process Technology, Carbon Fibers, and Composite Solutions. It offers products for automotive industries, including body and main parts; carbon-ceramic brake discs; body shell components; battery solutions; friction materials; chassis components; gas diffusion layers and bipolar plates; vanes and rotors; sealing materials; bearings and mechanical seals; commutator discs and carbon brushes; and temperature management materials, as well as other products. The company also provides composite solutions, such as energy storage systems, lead springs, skin and structure, thermoplastic profiles, and friction components; fuel cells for energy conversion, as well as for passenger cars and trains, and ferries for zero emission mobile applications; and carbon fiber-reinforced plastics and composites for aerospace industry. In addition, it offers isostatic graphite to produce compound semiconductor layers; silicon carbide coatings for semiconductor production; and heat exchangers, columns, quenchers, pumps, components and assemblies, and pipings, as well as sealing materials for process technology. SGL Carbon SE was founded in 1878 and is headquartered in Wiesbaden, Germany.